Myriad Genetics (MYGN) Institutional Ownership

During the previous two years, 193 institutional investors and hedge funds held shares of Myriad Genetics. The most heavily invested institutionals were Camber Capital Management LP ($153.80M), Vanguard Group Inc. ($145.20M), State Street Corp ($128.83M), Glenview Capital Management LLC ($101.14M), Wellington Management Group LLP ($82.32M), Disciplined Growth Investors Inc. MN ($69.23M), and Loomis Sayles & Co. L P ($59.97M).Learn more on MYGN's institutional investors.

99.02% of Myriad Genetics stock is owned by institutional investors. Learn more on MYGN's institutional investor holdings.

Of the 164 institutional investors that purchased Myriad Genetics stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Glenview Capital Management LLC ($2.60M), Wellington Management Group LLP ($1.47M), Sei Investments Co. ($1.38M), Loomis Sayles & Co. L P ($1.33M), Vanguard Group Inc. ($1.16M), D. E. Shaw & Co. Inc. ($668.43K), and Artisan Partners Limited Partnership ($667.98K).

Institutional investors have bought a total of 20,225,966 shares in the last 24 months. This purchase volume represents approximately $417.09M in transactions.

Of the 95 institutional investors that sold Myriad Genetics stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: Wellington Management Group LLP ($3.03M), Point72 Asset Management L.P. ($715.11K), Bank of America Corp DE ($495.91K), Camber Capital Management LP ($365K), Assenagon Asset Management S.A. ($229.60K), Mirae Asset Global Investments Co. Ltd. ($228.29K), and Dimensional Fund Advisors LP ($202.05K).

Institutional investors have sold a total of 7,927,254 shares in the last 24 months. This volume of shares sold represents approximately $150.55M in transactions.